Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients-Reference-Cited by-同舟云学术

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients

Published:2019-06 Issue: Volume:16 Page:100237
ISSN:2212-1374
Container-title:Journal of Bone Oncology
language:en
Short-container-title:Journal of Bone Oncology

Author:

Göbel Andy,Kuhlmann Jan D.,Link Theresa,Wimberger Pauline,Link-Rachner Cornelia,Thiele Stefanie,Dell'Endice Stefania,Furesi Giulia,Breining Dorit,Rauner Martina,Hofbauer Lorenz C.,Rachner Tilman D.

Funder

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. The role of Semaphorin 4d in bone remodeling and cancer metastasis;Lontos;Front Endocrinol. (Lausanne),2018

2. Suppression of bone formation by osteoclastic expression of Semaphorin 4D;Negishi-Koga;Nat. Med.,2011

3. Control of bone resorption by Semaphorin 4D Is dependent on ovarian function;Dacquin;PLoS One,2011

4. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma;Terpos;Blood Cancer J.,2018

5. Regulation of semaphorin 4D expression and cell proliferation of ovarian cancer by ERalpha and ERbeta;Liu;Braz. J. Med. Biol. Res.,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leptin and melatonin’s effects on OVX rodents’ bone metabolism;Frontiers in Endocrinology;2023-06-27

2. Class IV semaphorins in disease pathogenesis;Pathology International;2022-09-06

3. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer;Theranostics;2021